Drug Profile
Research programme: peroxidase antimicrobial therapeutics - Exoxemis
Alternative Names: C-101 - ExoxemisLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Exoxemis
- Class Peroxidases
- Mechanism of Action Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections in USA (Topical)
- 11 Sep 2012 Early research in Bacterial infections in USA (Topical)
- 11 Sep 2012 Antimicrobial data from an early research study presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)